Pfizer Signs a Worldwide License Agreement with Theravance BioPharma for its Pan-JAK Inhibitor Program

Pfizer Signs a Worldwide License Agreement with Theravance BioPharma for its Pan-JAK Inhibitor Program

Shots:

  • Theravance to receive $10M up front, up to $240M development & commercial milestones with royalties on global sales of any product developed from the program. Pfizer to get a global license for Theravance’s skin-targeted, LA, pan-Janus kinase (JAK) inhibitors  
  • Pfizer will validate Theravance’s expertise in the discovery & development of organ-selective JAK inhibitors while the program will complement Pfizer’s portfolio of pre/ clinical-stage molecules targeting unmet medical needs
  • JAK inhibitors act by targeting the JAK enzyme, thus interfering with the JAK/STAT signaling pathway which resulted in modulating the activity of a wide range of pro-inflammatory cytokines. The compounds in the program are designed to possess skin-selective activity with minimal systemic exposure

Click here ­to­ read full press release/ article | Ref: Theravance | Image: Office Snapshot